FORA.NASDAQForian INC

10-Q: Forian Q2 Profit Surges on Kyber Acquisition, Revenue Up 56%

Sentiment:

Quarterly Report


Forian Inc. reported a significant turnaround to net income in Q2 2025, driven by strong revenue growth from the Kyber acquisition and improved operational efficiency, despite ongoing vendor data challenges.

Better than expectedNet income of $224,793 for Q2 2025, a significant improvement from a net loss of $(2,553,259) in Q2 2024.Operating income of $46,076 for Q2 2025, a turnaround from an operating loss of $(2,970,478) in Q2 2024.Adjusted EBITDA increased by 655.8% in Q2 2025 and 195.9% for the six months ended June 30, 2025.Positive cash flow from operating activities of $103,649 for the six months ended June 30, 2025, compared to a negative cash flow in the prior year.Significant reduction in net loss for the six months ended June 30, 2025, to $(901,069) from $(3,765,874) in the prior year.

Summary

  • Forian Inc. achieved net income of $224,793 for the three months ended June 30, 2025, a substantial improvement from a net loss of $(2,553,259) in the prior year period.
  • Revenue for Q2 2025 increased by 56.5% to $7,476,140, up from $4,777,101 in Q2 2024, primarily due to the acquisition of Kyber Data Science, LLC and organic growth.
  • Year-to-date (six months ended June 30, 2025) revenue grew by 50.5% to $14,532,256, compared to $9,654,479 in the same period of 2024.
  • Adjusted EBITDA for Q2 2025 surged to $591,073 from $78,202 in Q2 2024, an increase of 655.8%.
  • The company reported positive cash flow from operating activities of $103,649 for the six months ended June 30, 2025, a significant improvement from a cash outflow of $(2,231,180) in the prior year.
  • Gross profit as a percentage of revenues decreased to 57% for Q2 2025 (from 62% in Q2 2024) and 56% for YTD Q2 2025 (from 64% in YTD Q2 2024), primarily due to higher information licensing and processing expenses.
  • Litigation settlements and related expenses decreased to $0 in Q2 2025 from $942,311 in Q2 2024, as legacy claims from the Helix merger were settled.
  • The company's cash and marketable securities totaled $35,649,025 as of June 30, 2025.

Sentiment

Score: 7

Explanation: The company demonstrated strong financial performance with a significant increase in revenue and a return to net income for the quarter, driven by a successful acquisition and improved operational efficiency. However, ongoing material weaknesses in internal controls and challenges with key data vendors present notable concerns that temper overall sentiment.

Positives

  • Achieved net income of $224,793 for Q2 2025, a significant turnaround from a net loss of $(2,553,259) in Q2 2024.
  • Revenue increased by 56.5% to $7,476,140 in Q2 2025 and by 50.5% to $14,532,256 for the six months ended June 30, 2025, driven by the Kyber acquisition and organic growth.
  • Adjusted EBITDA saw a substantial increase of 655.8% to $591,073 in Q2 2025 and 195.9% to $540,295 for the six months ended June 30, 2025.
  • Generated positive cash flow from operating activities of $103,649 for the six months ended June 30, 2025, compared to a significant cash outflow in the prior year.
  • Litigation settlements and related expenses were $0 in Q2 2025, down from $942,311 in Q2 2024, indicating resolution of past legal issues.
  • General and administrative expenses decreased by $1,257,798 in Q2 2025 and $1,262,193 for the six months ended June 30, 2025, primarily due to lower stock compensation and credit loss expense.
  • Interest expense decreased significantly due to the redemption of convertible notes in 2024.
  • Strong cash and marketable securities balance of $35,649,025 provides liquidity.

Negatives

  • Gross profit as a percentage of revenues decreased to 57% in Q2 2025 (from 62% in Q2 2024) and 56% for the six months ended June 30, 2025 (from 64% in the prior year), primarily due to higher information licensing and processing expenses.
  • Research and development expenses increased by $368,530 in Q2 2025 and $584,878 for the six months ended June 30, 2025, primarily due to the Kyber acquisition.
  • Sales and marketing expenses increased by $478,051 in Q2 2025 and $805,637 for the six months ended June 30, 2025, due to the Kyber acquisition and increased salesperson compensation.
  • Interest and investment income decreased by $270,348 in Q2 2025 and $616,657 for the six months ended June 30, 2025, primarily due to lower investment in treasury bills.
  • Material weaknesses in internal controls over financial reporting remain ineffective as of June 30, 2025.
  • Reliance on a single customer for 11.4% of Q2 2025 revenue and three customers for a significant portion of accounts receivable (18.5%, 17.3%, and 10.4%).

Risks

  • Disruptions associated with third-party information vendors could have a material short-term impact if alternate sources of comparable data cannot be secured on equivalent terms.
  • One information vendor will no longer include certain data after December 31, 2024, and intends to exit the data licensing business by the end of 2026, requiring the company to seek alternate data sources.
  • Internal controls over financial reporting were deemed ineffective as of June 30, 2025, due to identified material weaknesses, which could affect the accuracy and reliability of financial reporting.
  • Estimates and assumptions used in financial statements, particularly for revenues, stock-based compensation, income taxes, and business combinations, are inherently uncertain and could differ from actual results.
  • The company has significant customer concentration, with one customer representing 11.4% of Q2 2025 revenue and three customers accounting for a large portion of accounts receivable.
  • The remaining $6,000,000 principal of convertible notes, plus accrued interest ($6,804,016 total), matures on September 1, 2025, requiring repayment or conversion.

Future Outlook

The company expects to continue funding its operations and potential future acquisitions through a combination of cash flow generated from operating activities, available cash and marketable securities, debt financing, and/or additional equity issuances. It is also assessing the impacts of recently enacted U.S. federal income tax law changes (OBBBA) and evaluating the impact of new accounting pronouncements (ASU 2023-09, ASU 2024-03, ASU 2025-05) on its consolidated financial statements and related disclosures.

Management Comments

  • The increase in revenue is primarily due to the impact of the acquisition of Kyber and organic growth in sales of the Company's information products.
  • The decrease in general and administrative expenses is primarily due to lower stock compensation expense and decreased credit loss expense.
  • The decrease in interest expense is due to the impact of the redemption of the Company's convertible notes in 2024.
  • The increase in Adjusted EBITDA is primarily due to higher revenues, partially offset by the increased cost of revenues and other operating expenses.
  • The Company plans to license data from additional vendors in consideration of the above changes; however, there can be no assurance that the alternate sources of comparable data can be obtained, and if so, on terms and conditions substantially equivalent to those under the Company's previous agreement.
  • The Company is currently assessing and improving the operating effectiveness of these controls to ensure they will operate at an acceptable level of assurance.

Industry Context

Forian operates in the dynamic data management and analytics solutions sector, serving the healthcare, life sciences, and financial services industries. The acquisition of Kyber Data Science strengthens its position in financial services. The challenges with information vendors highlight the critical importance of data supply chain resilience in this industry, where access to comprehensive and reliable data is paramount for product offerings. The company's growth, despite these vendor issues, suggests strong demand for its core analytics products.

Comparison to Industry Standards

  • The filing does not provide specific comparable companies, projects, or results to assess performance against global benchmarks.
  • The significant revenue growth and positive Adjusted EBITDA, coupled with a move to net income, suggest a strong operational performance relative to its own prior periods, which could be indicative of outperformance in its niche markets, especially given the successful integration of Kyber Data Science.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Equity Incentive Plan AmendmentStockholders approved an amendment to the 2020 Equity Incentive Plan on June 11, 2025, increasing the number of shares available for issuance by 4,000,000 to a total of 10,400,000 shares.2025-06-11Increases the pool of shares available for stock-based compensation, potentially impacting dilution but also providing more flexibility for employee incentives.

Legal Proceedings

  • Audet v. Green Tree International, et. al.: A complaint filed on February 14, 2020, claiming 10% ownership of GTI, was settled and dismissed with prejudice on March 27, 2024.
  • Grant Whitus et al. v. Forian Inc., Zachary Venegas and Scott Ogur: A lawsuit filed on July 30, 2021, by former Helix employees claiming breach of contract and other issues, seeking over $27.5 million, was settled and dismissed with prejudice on June 7, 2024.

Related Party Transactions

  • A director's spouse holds $6,000,000 in principal of the 3.5% Convertible Promissory Notes due September 1, 2025.
  • Entered into a customer agreement on September 4, 2024, with an entity controlled by one of its directors, providing for products and services over a three-year period with aggregate minimum billings of $1,200,000 and noncash consideration of $133,914. Revenues from this agreement were $113,391 for Q2 2025 and $217,856 for YTD Q2 2025.
  • Adam Dublin, Chief Strategy Officer, received runoff commissions of $0 for Q2 2025 and $7,975 for YTD Q2 2025 from a former vendor.

Stakeholder Impact

  • Shareholders: Potential dilution from increased stock plan shares, but improved financial performance and reduced losses are positive. Resolution of litigation reduces contingent liabilities.
  • Employees: Grant of 600,000 restricted stock units provides additional incentives.
  • Customers: Kyber acquisition expands service offerings in financial services. Potential impact from vendor data changes could affect product quality or availability if alternate sources are not secured.
  • Creditors: The company has a strong cash and marketable securities position to address the upcoming maturity of convertible notes.
  • Suppliers/Vendors: Changes in vendor relationships, including one vendor exiting the data licensing business, indicate potential shifts in the company's supply chain for critical information assets.

Next Steps

  • License data from additional vendors to mitigate risks from existing vendor changes.
  • Continue assessing and improving the operating effectiveness of internal controls over financial reporting to remediate identified material weaknesses.
  • Evaluate the impact of new accounting pronouncements (ASU 2023-09, ASU 2024-03, ASU 2025-05) on consolidated financial statements.
  • Repay or convert the remaining $6,000,000 principal of convertible notes due September 1, 2025.
  • Recognize unrecognized stock compensation expense of $4,283,136 over a weighted-average period of approximately 1.5 years.

Key Dates

DateDescription
2020-10-15Forian Inc. incorporated in Delaware.
2021-09-01Issued $24,000,000 in aggregate principal balance of 3.5% Convertible Promissory Notes due September 1, 2025.
2022-06-15Stockholders approved an amendment to the 2020 Equity Incentive Plan, increasing shares available for issuance by 2,400,000 to a total of 6,400,000 shares.
2023-02-10Sold Bio-Tech Medical Software, Inc. (BioTrack) for $30,000,000, consisting of $20,000,000 cash at closing and a $10,000,000 note.
2023-07-21Sold a minority equity interest in a customer for cash proceeds of $5,805,858 and future contingent earnout payments up to $3,600,000 in 2025 and 2026.
2024-02-01The $10,000,000 note from the BioTrack sale was fully paid.
2024-02-28Redeemed $1,000,000 in principal and $87,356 of accrued interest on convertible notes for an aggregate redemption price of $950,000, resulting in a gain of $137,356.
2024-03-08Entered into a Settlement Agreement and General Release in the Audet v. Green Tree International, et. al. legal proceeding.
2024-03-18Filed a Joint Stipulation to Dismiss with Prejudice in the Audet v. Green Tree International, et. al. legal proceeding.
2024-03-27Court entered a Final Order of Dismissal with Prejudice in the Audet v. Green Tree International, et. al. legal proceeding.
2024-04-11Filed Annual Report on Form 10-K for the year ended December 31, 2024.
2024-05-31Remaining parties entered into a Settlement Agreement and Release in the Grant Whitus et al. v. Forian Inc., Zachary Venegas and Scott Ogur legal proceeding.
2024-06-07Plaintiffs filed a Stipulation of Dismissal and the Court entered a Minute Order dismissing the Grant Whitus et al. v. Forian Inc., Zachary Venegas and Scott Ogur case with prejudice.
2024-07-01Renewed lease agreement for office space in Hingham, Massachusetts, for an initial term of two years.
2024-07-31Informed by an information vendor that certain data would no longer be included in licensed products effective December 31, 2024.
2024-09-04Entered into a customer agreement with an entity controlled by one of its directors, providing for products and services over a three-year period.
2024-09-23Informed by an information vendor that it was exercising the right to terminate the agreement effective September 25, 2024.
2024-10-31Acquired all outstanding equity interests of Kyber Data Science, LLC (Kyber Acquisition Date).
2024-11-11Redeemed $16,000,000 in principal amount and $1,794,110 of accrued interest on convertible notes for an aggregate redemption price of $17,648,406, resulting in a gain of $145,703.
2024-12-15ASU 2023-09 (Income Taxes) is effective for public business entities for annual periods beginning after this date.
2024-12-31One information vendor ceased including certain data within its licensed information products.
2025-02-01An information vendor announced its intention to exit the data licensing business by the end of 2026.
2025-06-11Stockholders approved an amendment to the 2020 Equity Incentive Plan, increasing shares available for issuance by 4,000,000 to a total of 10,400,000 shares.
2025-06-19Kyber Aesthetic Data LLC and Kyber Survey Data LLC merged into Kyber Data Science LLC.
2025-06-30End of the reported fiscal quarter.
2025-07-02Entered into a Termination and Wind Down Agreement with a vendor, providing for a reduction of fees by $175,000.
2025-07-04U.S. government enacted the One Big Beautiful Bill Act ('OBBBA').
2025-07-15Board approved the grant of an aggregate of 600,000 restricted stock units to certain employees.
2025-08-1331,112,312 shares outstanding of common stock.
2025-08-14Date of filing of the Quarterly Report on Form 10-Q.
2025-09-01Maturity date for the 3.5% Convertible Promissory Notes.
2025-12-15ASU 2025-05 (Financial Instruments Credit Losses) is effective for annual reporting periods beginning after this date.
2026-12-15ASU 2024-03 (Income Statement Expense Disaggregation Disclosures) is effective for annual periods beginning after this date.
2026-12-31One information vendor intends to exit the data licensing business by this date.

Recommendation

hold

Forian Inc. demonstrated strong operational improvements, achieving net income for the quarter and significantly reducing its year-to-date loss, driven by robust revenue growth from the Kyber acquisition and improved cost management. The positive cash flow from operations and substantial cash reserves provide a solid financial foundation. However, the persistent material weaknesses in internal controls over financial reporting and the strategic challenge of securing alternative data sources due to vendor changes introduce notable uncertainties. While the financial trajectory is positive, these unresolved issues warrant a 'hold' recommendation, suggesting investors monitor the remediation of internal controls and the successful diversification of data suppliers before considering further investment.

Keywords

Forian Inc., FORA, SEC Filing, 10-Q, Quarterly Report, Financial Results, Data Management, Analytics Solutions, Healthcare Industry, Life Sciences, Financial Services, Kyber Acquisition, Revenue Growth, Net Income, Adjusted EBITDA, Cash Flow, Convertible Notes, Internal Controls, Vendor Risk, Customer Concentration

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.